Understanding Model Based Designs In Oncology Dose Finding Studies
Welcome to our comprehensive guide on Model Based Designs In Oncology Dose Finding Studies. Takeda Pharmaceuticals, Biostatistician, Ling Wang shares the lessons learned in adopting
Key Takeaways about Model Based Designs In Oncology Dose Finding Studies
- Innovations in statistics, programming and data management are changing the very nature of clinical development.
- Historically, phase 1
- Ying Lu Stanford University, USA.
- Yannis Jeimiai, Vice President, Cytel Beginning with an overview of applicable adaptive approaches and the current regulatory ...
- The objectives of this webinar are: To understand the role of phase I
Detailed Analysis of Model Based Designs In Oncology Dose Finding Studies
Innovations in statistics, programming and data management are changing the very nature of clinical development. Webinar by Dr. Yuan Ji (University of Chicago) Historically, single-arm phase 2
Join Phase 2 development trial
In summary, understanding Model Based Designs In Oncology Dose Finding Studies gives us a better perspective.